Clinical Trials

    Showing 1 - 6 of 6 Cirrhosis

    Guerbet Study

    Status: Open Not Enrolling

    Investigator: Dipan Shah

    Study Coordinator: Fareeha Dadabhoy

    Phone: 713.441.2116

    This study is designed to evaluate the efficacy of Dotarem enhanced MRI compared to Magnevist and Gadavist enhanced MRI in identifying myocardial infarct. Eighty patients will be recruited for this study. Patients with known CAD and undergoing clinic... Read more >

    A Phase 2, Randomized, Placebo-Controlled Study to Evaluate Fingolimod for the Abrogation of Interstitial Fibrosis and Tubular Atrophy Following Kidney Transplantation

    Status: Enrolling

    Investigator: Ahmed Gaber

    Study Coordinator: Jack Curtis

    Phone: 913.486.9249

    This is a randomized, double-blind, placebo-controlled trial in de novo kidney transplant patients to determine if the addition of fingolimod (brand name Gilenya®, candidate name- FTY720) on the background of standard immunosuppression will prevent e... Read more >

    A Randomized, Double-blind, Placebo-controlled, Multinational, Phase 3 Study of the Efficacy and Safety of Inhaled Treprostinil in Subjects with Progressive Pulmonary Fibrosis (TETON-PPF)

    Status: Enrolling

    Investigator: Sandeep Sahay

    Study Coordinator: Rosa Barrosa da Costa

    Phone: 713.441.5660

    Study RIN-PF-305 is designed to evaluate the safety and efficacy of inhaled treprostinil in subjects with progressive pulmonary fibrosis (PPF) over a 52-week period.... Read more >

    A Study Evaluating Atezolizumab, With or Without Bevacizumab, in Patients With Unresectable Hepatocellular Carcinoma and Child-Pugh B7 and B8 Cirrhosis (Kirros)

    Status: Open Not Enrolling

    Investigator: Maen Abdelrahim

    Study Coordinator: Safiya Joseph

    Phone: 203.308.8567

    The purpose of this study is to assess the safety and efficacy of atezolizumab and bevacizumab, or atezolizumab alone, as first-line treatment in participants with unresectable, locally advanced or metastatic hepatocellular carcinoma (HCC) with Child... Read more >

    HCMR - Novel

    Status: Open Not Enrolling

    Investigator: Sherif Nagueh

    Study Coordinator: Alharith Humadi

    Phone: 346.238.4551

    Hypertrophic cardiomyopathy (HCM) is the most common monogenic heart disease and the most frequent cause of sudden cardiac death (SCD) in the young. It is characterized by unexplained left ventricular hypertrophy (LVH), diffuse and patchy fibrosis, a... Read more >

    Idiopathic Pulmonary Fibrosis and Interstitial Lung Disease Prospective Outcomes Registry (IPF/ILD-PRO)

    Status: Enrolling

    Investigator: Zeenat Safdar

    Study Coordinator: Jennifer Lee

    Phone: 713.363.7537

    This registry will collect data on the strategies used to achieve a diagnosis of Idiopathic Pulmonary Fibrosis (IPF) and Chronic Fibrosing Interstitial Lung Disease with Progressive Phenotype (ILD) and the treatment and management efforts applied thr... Read more >